New strategies in sarcoma therapy: Linking biology and novel agents

Clinical Cancer Research

Volumn 18, Issue 21, 2012, Pages 5837-5844

  Janeway, Katherine A ^a   Maki, Robert G ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ANTINEOPLASTIC AGENT; CIXUTUMUMAB; CRENALONIB; CRIZOTINIB; CYCLIN DEPENDENT KINASE 4 INHIBITOR; DENOSUMAB; FIGITUMUMAB; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD2; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; HUMAN HOMOLOGUE OF MURINE DOUBLE MINUTE 2 INHIBITOR; IMATINIB; INTERLEUKIN 1; LISITINIB; MIFAMURTIDE; MONOCLONAL ANTIBODY; OLAPARIB; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN MDM2; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RG 7112; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN C RECEPTOR ANTIBODY; SOMATOMEDIN C RECEPTOR MONOCLONAL ANTIBODY R 1507; TEMOZOLOMIDE; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; CHILDHOOD CANCER; DRUG RESEARCH; EWING SARCOMA; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; LIPOSARCOMA; LUNG NON SMALL CELL CANCER; OSTEOCLASTOMA; OSTEOSARCOMA; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CELL GRANULOMA; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; RHABDOMYOSARCOMA; SARCOMA; SYNOVIAL SARCOMA; TREATMENT RESPONSE; WELL DIFFERENTIATED DEDIFFERENTIATED LIPOSARCOMA;

AGE FACTORS; ANTINEOPLASTIC AGENTS; HUMANS; SARCOMA;

EID: 84868518795     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0875     Document Type: Review

References (58)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Fletcher CDM, Unni KK, Mertens F, editors. Pathology and genetics of tumours of soft tissue and bone. Lyon, France: IARC Press; 2002.
3. Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med 2005;353:701-11. (Pubitemid 41175678)
4. Taylor BS, Barretina J, Maki RG, Antonescu CR, Singer S, Ladanyi M. Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer 2011;11:541-57.
5. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, DeCarolis PL, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 2010;42:715-21.
6. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009;115:1531-43.
7. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;363:1324-34.
8. Heiner JP, Miraldi F, Kallick S, Makley J, Neely J, Smith-Mensah WH, et al. Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma. Cancer Res 1987;47:5377-81. (Pubitemid 17152948)
9. Frost JD, Hank JA, Reaman GH, Frierdich S, Seeger RC, Gan J, et al. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer 1997;80:317-33. (Pubitemid 27282327)
10. Mori K, Le Goff B, Berreur M, Riet A, Moreau A, Blanchard F, et al. Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. J Pathol 2007;211:555-62. (Pubitemid 46502432)
11. Mori K, Berreur M, Blanchard F, Chevalier C, Guisle-Marsollier I, Masson M, et al. Receptor activator of nuclear factor-kappaB ligand (RANKL) directlymodulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. Oncol Rep 2007;18:1365-71.
12. Lamoureux F, Picarda G, Rousseau J, Gourden C, Battaglia S, Charrier C, et al. Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma. Mol Cancer Ther 2008;7:3389-98.
13. Lamoureux F, Richard P, Wittrant Y, Battaglia S, Pilet P, Trichet V, et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res 2007;67:7308-18. (Pubitemid 47206560)
14. Akiyama T, Choong PF, Dass CR. RANK-Fc inhibits malignancy via inhibiting ERK activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells. Clin Exp Metastasis 2010;27:207-15.
15. Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010;11:275-80.
16. Kolb EA, Gorlick R. Development of IGF-IR inhibitors in pediatric sarcomas. Curr Oncol Rep 2009;11:307-13.
17. Juergens H, Daw NC, Geoerger B, Ferrari S, Villarroel M, Aerts I, et al. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 2011;29:4534-40.
18. Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 2011;29:4541-7.
19. Fidler MJ, Shersher DD, Borgia JA, Bonomi P. Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls. Ther Adv Med Oncol 2012;4:51-60.
20. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012;483:570-5.
21. Brenner JC, Feng FY, Han S, Patel S, Goyal SV, Bou-Maroun LM, et al. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res 2012;72:1608-13.
22. Soldatenkov VA, Albor A, Patel BK, Dreszer R, Dritschilo A, Notario V. Regulation of the human poly(ADP-ribose) polymerase promoter by the ETS transcription factor. Oncogene 1999;18:3954-62. (Pubitemid 29361333)
23. clinicaltrials.gov. Olaparib in adults with recurrent/metastatic Ewing's sarcoma, NCT01583543. [Accessed 2012 June 1; cited 2012 June 1]. Available from: http://clinicaltrials.gov/ct2/show/NCT01583543.
24. Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the Children's Oncology Group (COG) soft-tissue sarcoma committee experience and rationale for current COG studies. Pediatr Blood Cancer 2012;59:5-10.
25. Bridge JA, Kanamori M, Ma Z, Pickering D, Hill DA, Lydiatt W, et al. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol 2001;159:411-5. (Pubitemid 32751070)
26. Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KS, Perlman E, Griffin CA. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol 2001;14:569-76. (Pubitemid 32554081)
27. Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010;363:1727-33.
28. clinicaltrials.gov. Crizotinib in treating young patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma, trial NCT00939770. [Accessed 2012 June 2; cited 2012 June 2]. Available from: http:// clinicaltrials.gov/ct2/show/NCT00939770.
29. Mossé YP, Balis FM, Lim MS, Laliberte J, Voss SD, Fox E, et al. Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: a Children's Oncology Group phase I consortium study. J Clin Oncol 30, 2012 (suppl; abstr 9500).
30. Joensuu H, DeMatteo RP. The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy. Annu Rev Med 2012;63:247-58.
31. Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schutte J, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012;307:1265-72.
32. Janeway KA, Weldon CB. Pediatric gastrointestinal stromal tumor. Semin Pediatr Surg 2012;21:31-43.
33. Janeway KA, Kim SY, Lodish M, Nose V, Rustin P, Gaal J, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A 2011;108:314-8.
34. Haldar M, Hancock JD, Coffin CM, Lessnick SL, Capecchi MR. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell 2007;11:375-88. (Pubitemid 46518310)
35. Saito T, Nagai M, Ladanyi M. SYT-SSX1 and SYT-SSX2 interfere with repression of E-cadherin by snail and slug: a potential mechanism for aberrant mesenchymal to epithelial transition in human synovial sarcoma. Cancer Res 2006;66:6919-27. (Pubitemid 44197666)
36. Nguyen A, Su L, Campbell B, Poulin NM, Nielsen TO. Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma. Sarcoma 2009;2009:794901.
37. Terry J, Lubieniecka JM, Kwan W, Liu S, Nielsen TO. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models. Clin Cancer Res 2005;11:5631-8. (Pubitemid 41060842)
38. Su L, Cheng H, Sampaio AV, Nielsen TO, Underhill TM. EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor. Oncogene 2010;29:4352-61.
39. Lubieniecka JM, de Bruijn DR, Su L, van Dijk AH, Subramanian S, van de Rijn M, et al. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. Cancer Res 2008;68:4303-10.
40. Su L, Sampaio AV, Jones KB, Pacheco M, Goytain A, Lin S, et al. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell 2012;21:333-47.
41. Taylor BS, Decarolis PL, Angeles CV, Brenet F, Schultz N, Antonescu CR, et al. Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas. Cancer Discov 2011;1:587-97.
42. Garsed DW, Holloway AJ, Thomas DM. Cancer-associated neochromosomes: a novel mechanism of oncogenesis. Bioessays 2009;31:1191-200.
43. Millard M, Pathania D, Grande F, Xu S, Neamati N. Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update. Curr Pharm Des 2011;17:536-59.
44. Flaherty KT, Lorusso PM, Demichele A, Abramson VG, Courtney R, Randolph SS, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 2012;18:568-76.
45. clinicaltrials.gov. Temozolomide, cixutumumab, and combination chemotherapy in treating patients with metastatic rhabdomyosarcoma, trial NCT01055314. [Accessed 2012 June 2; cited 2012 June 2]. Available from: http://clinicaltrials.gov/ct2/show/NCT01055314.
46. Walkley CR, Qudsi R, Sankaran VG, Perry JA, Gostissa M, Roth SI, et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev 2008;22:1662-76. (Pubitemid 351846845)
47. Keller C, Capecchi MR. New genetic tactics to model alveolar rhabdomyosarcoma in the mouse. Cancer Res 2005;65:7530-2. (Pubitemid 41297220)
48. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group. J Clin Oncol 2008;26:633-8. (Pubitemid 351264359)
49. Ando K, Mori K, Corradini N, Redini F, Heymann D. Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opin Pharmacother 2011;12:285-92.
50. Kleinerman ES, Maeda M, Jaffe N. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma. Cancer Treat Res 1993;62:101-7.
51. Grignani G, Palmerini E, Dileo P, Asaftei SD, D'Ambrosio L, Pignochino Y, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol 2012;23:508-16.
52. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879-86.
53. Gardner K, Judson I, Leahy M, Barquin E, Marotti M, Collins B, et al. Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma. J Clin Oncol 27:15s, 2009 (suppl; abstr 10523).
54. Stacchiotti S, Negri T, Zaffaroni N, Palassini E, Morosi C, Brich S, et al. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol 2011;22:1682-90.
55. Edris B, Espinosa I, Muhlenberg T, Mikels A, Lee CH, Steigen SE, et al. ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. J Pathol 2012;227:223-33.
56. Schwartz GK, Maki RG, Ratain MJ, Undevia SD, Jones RL, Rudin CM, et al. Brivanib (BMS-582664) in advanced soft-tissue sarcoma: biomarker and subset results of a phase II randomized discontinuation trial. J Clin Oncol 29: 2011 (suppl; abstr 10000).
57. Vernon CB, Eary JF, Rubin BP, Conrad EU III, Schuetze S. FDG PET imaging guided re-evaluation of histopathologic response in a patient with high-grade sarcoma. Skeletal Radiol 2003;32:139-42. (Pubitemid 36818113)
58. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753-9. (Pubitemid 46797957)